Arrowhead Pharmaceuticals (MEX:ARWR) Market Cap: MXN198,501 Mil (As of Jul. 02, 2026)


MEX:ARWR Arrowhead Pharmaceuticals Inc MEX:ARWR
49 GF Score
Price MXN454.55
GF Value MXN293.33
! 7 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Market Cap?

Arrowhead Pharmaceuticals MEX:ARWR 49 Market Cap is MXN198,501 Mil as of Jul. 02, 2026. GuruFocus rates MEX:ARWR with a GF Score™ of 49/100 and a GF Value™ of MXN293.33. The stock has 7 warning signs investors should review. Among 1,427 Biotechnology companies, Arrowhead Pharmaceuticals ranks better than 97.83% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Arrowhead Pharmaceuticals's share price for the quarter that ended in Mar. 2026 was MXN454.55. Arrowhead Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 141 Mil. Therefore, Arrowhead Pharmaceuticals's market cap for the quarter that ended in Mar. 2026 was MXN63,897 Mil.

Arrowhead Pharmaceuticals's quarterly market cap increased from Sep. 2025 (MXN61,683 Mil) to Dec. 2025 (MXN62,451 Mil) and increased from Dec. 2025 (MXN62,451 Mil) to Mar. 2026 (MXN63,897 Mil).

Arrowhead Pharmaceuticals's annual market cap increased from Sep. 2023 (MXN62,885 Mil) to Sep. 2024 (MXN72,884 Mil) but then declined from Sep. 2024 (MXN72,884 Mil) to Sep. 2025 (MXN61,683 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Arrowhead Pharmaceuticals's Enterprise Value for Today is MXN184,316 Mil.


Arrowhead Pharmaceuticals  (MEX:ARWR) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Arrowhead Pharmaceuticals Market Cap Related Terms


Arrowhead Pharmaceuticals Market Cap Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Market Cap Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 130,408.75 148,238.04 62,884.83 72,884.34 61,683.34

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62,756.08 62,793.36 61,683.34 62,451.08 63,896.55

MEX:ARWR vs CYTK, TECH, KRYS: Market Cap Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Market Cap falls into.


MEX:ARWR
49GF Score
Arrowhead Pharmaceuticals Inc MEX:ARWR
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Arrowhead Pharmaceuticals's Market Cap for the fiscal year that ended in Sep. 2025 is calculated as

Market Cap (A: Sep. 2025 )=Share Price (A: Sep. 2025 )*Shares Outstanding (EOP) (A: Sep. 2025 )
=MXN454.55*135.702
=MXN61,683

Arrowhead Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=MXN454.55*140.571
=MXN63,897

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of MXN198,501 Mil mean?
Arrowhead Pharmaceuticals (MEX:ARWR) has a Market Cap of MXN198,501 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arrowhead Pharmaceuticals and its competitors. According to the industry distribution chart, Arrowhead Pharmaceuticals ranks #31 out of 1427 companies in the Biotechnology industry, placing it in the top 2.2%.
Is Arrowhead Pharmaceuticals' Market Cap too high?
Arrowhead Pharmaceuticals' current Market Cap is MXN198,501 Mil. Based on the distribution chart, Arrowhead Pharmaceuticals ranks #31 out of 1427 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Market Cap compare to CYTK and TECH?
According to the Biotechnology industry distribution chart, Arrowhead Pharmaceuticals ranks #31 out of 1427 companies for Market Cap. This places Arrowhead Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Market Cap is 119.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.04, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Arrowhead Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 119.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arrowhead Pharmaceuticals's current Market Cap is MXN198,501 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current Market Cap of MXN198,501 Mil. The stock's GF Value™ is MXN293.33, compared to a current price of MXN454.55 — trading 55% above its estimated fair value. The current Market Cap is MXN198,501 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current Market Cap is MXN198,501 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of MXN454.55 is trading 55% above its estimated GF Value™ of MXN293.33.

Key valuation signals for MEX:ARWR:

  • Market Cap: MXN198,501 Mil
  • GF Value™: MXN293.33 vs. price of MXN454.55 (55% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for MEX:ARWR

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN454.55
Price
MXN293.33
GF Value